News

The Pros & Cons of Vaporization

June 12, 2021
|
The EO Team

An Analysis of Cannabis Vaporization Among Medical Users

Researchers have recently analyzed popular vaping behavior and revealed the advantages of vaporizing medical cannabis. The general advantages of vaporizing medical cannabis include portability, concealability, and efficiency, while the medical advantages like promoting tobacco cessation and it’s quick-acting effects. There are also limitations to vaporization, like technology-use barriers for those who find technology difficult to work with and the cost of such devices. Vaporizing may also prove to be advantageous or disadvantageous for patients depending on their medical condition, meaning that all patients should discuss consumption mechanisms with their physician.

As the cannabis industry continues to grow various consumption methods become readily available for consumers, each presenting its own benefits and limitations.

Patients should thoroughly research the different consumption methods and discuss which method would work best for them. Vaporizers in the featured article were mainly portable but desktop vaporizers are also available and often more efficient. The world of edibles continues to grow and it better for those looking for longer-lasting, stronger, and delayed effects. Tinctures are easy to prepare at home or buy online and are ideal for incorporating into patients' favorite meals, smoothies, or can be taken sublingually for fast-acting effects and raw cannabinoids. Experimentation is encouraged, just be sure to start at a slow dose and slowly feel out the effects.

<-  Back to blog
More
News
News

Cannabis Rescheduling: A Turning Point for Symptom Management in Healthcare

A major policy shift is reshaping how providers and payers approach symptom management. Here’s what cannabis rescheduling means for clinical care, reimbursement, and patient outcomes.

Read More
Read More
News

EO Care Appoints William Fleming and Kristi Savacool to Board of Directors

EO Care has appointed healthcare leaders William Fleming (former Humana executive) and Kristi Savacool (former Aon Hewitt CEO) to its Board of Directors, strengthening governance as cannabinoid-based symptom management enters mainstream healthcare.

Read More
Read More
News

EO Care, Inc. Statement on Cannabinoid Policy Announcements

The Administration’s decision to move to reclassify cannabis from Schedule I to Schedule III is a watershed moment for adult Americans who currently or might benefit from the responsible use of cannabinoids, especially oncology patients and older adults. It’s a long overdue step that will reduce stigma, open doors for essential research and product development, and increase access to care for patients.

Read More
Read More